Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

erschienen in

Verlag

Geographic terms

Sprache

Datenbank

mehr ...

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 25 von 1567, Suchdauer: 0.81s

12 3 4 5 6 7 8 9 10 11 weiter »

1
Awareness of genomic testing among patients with breast cancer in Europe

von Cardone, Antonella ; Bell, Dany ; Biurrun, Conchi ; et al.

In The Breast June 2025 81
- View full text via DOI
Merkliste

2
The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

von Molinelli, Chiara ; Bruzzone, Marco ; Blondeaux, Eva ; et al.

In European Journal of Cancer December 2024 213
- View full text via DOI
Merkliste

3
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile

von Ascierto, Paolo A. ; Di Giacomo, Anna M. ; Chiarion Sileni, Vanna ; et al.

In European Journal of Cancer September 2023 191
- View full text via DOI
Merkliste

4
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

5
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

6
Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®)

von Caminiti, Caterina ; Bryce, Jane ; Riva, Silvia ; et al.

Schlagworte: Linguistic validation; PRO-CTCAE; cognitive interviewing; patient-reported outcome; symptomatic adverse events
- View full text via BASE
Merkliste

7
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study

von Cazzaniga, Marina Elena ; Pronzato, Paolo ; Amoroso, Domenico ; et al.

Schlagworte: HER2 negative; metastatic breast cancer; overall survival; progression free survival; time to treatment change
- View full text via BASE
Merkliste

8
Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials

von Burdett, Sarah ; Fisher, David J. ; Vale, Claire L. ; et al.

In European Urology January 2022 81(1):50-61
- View full text via DOI
Merkliste

9
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY

von Balmana, Judith ; Fasching, Peter A. ; Couch, Fergus J. ; et al.

Schlagworte: DNA-DAMAGE RESPONSE; CHEMOTHERAPY; SURVIVAL; Breast cancer 1 gene product; Breast cancer 2 gene product; Breast cancer; Olaparib; Kaplan-Meier survival curves; Progression-free survival; Overall survival
- View full text via BASE
Merkliste

10
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial

von Conte, Benedetta ; Bruzzone, Marco ; Lambertini, Matteo ; et al.

In European Journal of Cancer September 2020 136:43-51
- View full text via DOI
Merkliste

11
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial

von Del Mastro, Lucia ; Mansutti, Mauro ; Bisagni, Giancarlo ; et al.

In The Lancet Oncology October 2021 22(10):1458-1467
- View full text via DOI
Merkliste

12
The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey

von Di Noia, Vincenzo ; Renna, Davide ; Barberi, Vittoria ; et al.

In European Journal of Cancer August 2021 153:260-264
- View full text via DOI
Merkliste

13
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

von Timcheva, Constanta ; Tomova, Antoaneta ; Eisen, Andrea ; et al.

In European Journal of Cancer July 2021 152:68-77
- View full text via DOI
Merkliste

14
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study

von Conte, Benedetta ; Fabi, Alessandra ; Poggio, Francesca ; et al.

In Clinical Breast Cancer April 2020 20(2):e181-e187
- View full text via DOI
Merkliste

15
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

von Korach, Jacob ; Huzarski, Tomasz ; Byrski, Tomasz ; et al.

In The Lancet Oncology May 2021 22(5):620-631
- View full text via DOI
Merkliste

16
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer

von Grossi, Francesco ; Genova, Carlo ; Crinò, Lucio ; et al.

In European Journal of Cancer December 2019 123:72-80
- View full text via DOI
Merkliste

17
Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study

von Procopio, Giuseppe ; Apollonio, Giulia ; Cognetti, Francesco ; et al.

In European Urology Oncology November 2019 2(6):699-707
- View full text via DOI
Merkliste

18
Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx study

von Barni, Sandro ; Cognetti, Francesco ; Petrelli, Fausto

Breast Cancer Research and Treatment. 191(2):477-480
- Zum Volltext (via ReDI)
Merkliste

19
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials

von Daniele, Gennaro ; Arenare, Laura ; Scambia, Giovanni ; et al.

In Gynecologic Oncology July 2019 154(1):83-88
- View full text via DOI
Merkliste

20
p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study

von Fabi, Alessandra ; Mottolese, Marcella ; Di Benedetto, Anna ; et al.

In Clinical Breast Cancer December 2020 20(6):e761-e770
- View full text via DOI
Merkliste

21
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

von Cognetti, Francesco ; Masetti, Riccardo ; Fabi, Alessandra ; et al.

Schlagworte: breast cancer; real life; early stage
- View full text via BASE
Merkliste

22
Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients

von Garassino, Marina Chiara ; Gelibter, Alain Jonathan ; Grossi, Francesco ; et al.

In Journal of Thoracic Oncology August 2018 13(8):1146-1155
- View full text via DOI
Merkliste

23
The unmet need for oncofertility preservation in women: Results of a survey by different oncological specialists in Lazio, Italy

von Fabi, Alessandra ; Lanzetta, Gaetano ; Vizza, Enrico ; et al.

In Current Problems in Cancer December 2019 43(6)
- View full text via DOI
Merkliste

24
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

von Accurso, Antonello ; Agostara, Biagio ; Aieta, Michele ; et al.

In The Lancet Oncology April 2018 19(4):474-485
- View full text via DOI
Merkliste

25
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

von Harvey, Vernon ; Tomek, Rudolf ; Robert, Nicholas J. ; et al.

In The Lancet Oncology December 2017 18(12):1688-1700
- View full text via DOI
Merkliste

12 3 4 5 6 7 8 9 10 11 weiter »

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag